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SUMMARY – The purpose is to provide a twelve-month database review of screening for dia-
betic retinopathy (DR). A total of 1428 diabetes mellitus (DM) patients screened in 2017 were ana-
lyzed in a retrospective study. Retinal photographs were reviewed by an ophthalmologist for the pres-
ence and stage of DR, as well as for additional nondiabetic findings. The following grading categories 
of DR were used: without DR, mild non-proliferative DR (NPDR), moderate NPDR, severe non-
proliferative NPDR, proliferative DR (PDR), clinically significant macular edema (CSME) and un-
gradable finding. Severe NPDR, PDR and CSME were classified as vision-threatening DR. Out of 
1428 DM patients, 27 were diagnosed with type 1 DM and 1401 with type 2 DM, 353 of them had 
newly diagnosed type 2 DM. Without DR category was recorded in 85.2% of all eyes screened, 2.8% 
were ungradable, and 12% showed varying stages of DR. Vision-threatening DR was found in 2.8% 
and additional nondiabetic findings in 5.2% of all screened eyes. In the group of newly diagnosed type 
2 DM, 92.5% of screened eyes were without DR, 3.1% were ungradable and 4.3% showed varying 
stages of DR. In the group of newly diagnosed type 2 DM, vision-threatening DR was recorded in 
0.1% and additional nondiabetic finding in 5.7% of the eyes screened. In conclusion, a small propor-
tion of screened DM patients with detected DR had vision-threatening DR.
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Introduction
Diabetes mellitus (DM) is one of the world’s fast-
est growing chronic diseases and according to the 
World Health Organization, the global prevalence of 
DM is predicted to increase dramatically in the com-
ing decades, from an estimated 382 million in 2013 to 
592 million by 20351,2. Diabetic retinopathy (DR) is 
the most common microvascular complication of 
DM3. Consequently, DR is the leading cause of blind-
ness in working age individuals in industrialized coun-
tries and the fourth cause of blindness in developing 
countries in people of all age groups4,5. Therefore, 
screening for DR is important because early, timely 
and regular retinal examinations in patients with DM 
are crucial to detect DR stages that require prompt 
treatment of vision-threatening DR and thus enable 
prevention of DM related visual impairment6-9. DM 
patients who do not attend DR screenings are at an 
increased risk of developing vision-threatening DR10. 
In Europe, 50% of type 1 DM patients without DR at 
baseline were shown to develop DR within 5 to7 years, 
and 9% of those with mild non-proliferative DR (mild 
NPDR) would develop proliferative DR (PDR) by 5 
years11. In the UK, the 5-year cumulative DR inci-
dence in type 2 DM patients was 4%, rising to 16.4% 
after 10-year follow-up, from no retinopathy to pre-
PDR12. Most guidelines recommend annual screening 
for DR, so patients with type 1 DM are recommended 
to initiate screening 3-5 years after diagnosis and then 
yearly thereafter, whereas patients with type 2 DM are 
recommended to initiate screening at the time of diag-
nosis and then yearly thereafter13-16. Screening for eye 
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disease caused by DM with the current annual exami-
nation model is cost-effective since it saves money by 
reducing vision loss15,17.
In the National Program for Controlling Diabetes 
Mellitus 2010-2020, launched by the Ministry of 
Health of the Republic of Slovenia, the execution of 
systematic examinations of DM patients and screen-
ing for DR is planned. The Ministry of Health of the 
Republic of Slovenia has decided that screening for 
DR should be performed at eight Diabetic Retinopa-
thy Screening Service Centres, which are located in 
eight towns all over Slovenia. One of these Diabetic 
Retinopathy Screening Service Centres is at the De-
partment of Ophthalmology, Maribor University 
Clinical Centre in Maribor, where screening for DR 
has been performed since November 2015. The pur-
pose of this study was to provide a twelve-month re-
view of the results of screening for DR, with focus on 
the diagnosis made, referral rates and follow-up rec-
ommendations in all DM patients screened, the sub-
group of type 1 DM patients and subgroup of newly 
diagnosed type 2 DM patients.
Patients and Methods
This twelve-month retrospective database review 
conducted at Diabetic Retinopathy Screening Service 
Centre at Department of Ophthalmology, Maribor 
University Clinical Centre, Maribor, Slovenia, includ-
ed all DM patients screened between January and De-
cember 2017. All patients underwent a standardized 
protocol. Patient self-reported data on referral physi-
cian, age, gender, type of diabetes, duration of DM, 
DM therapy, and past ocular and general medical his-
tory were recorded. All procedures performed in this 
study were in accordance with ethical standards of the 
institutional and national Research Committees, 1964 
Helsinki Declaration and its later amendments or 
comparable ethical standards. Informed consent was 
obtained from all patients included in the study.
Presenting visual acuity (VA) at distance was re-
corded for each eye before dilating pupils for fundus 
photography. VA was measured with the patient wear-
ing their ‘walk-in’ optical correction (i.e. spectacles or 
contact lenses) using decimal equivalents of Snellen 
chart. If the patient was unable to read the largest let-
ter at 5 m with subjective refraction, then VA was re-
corded as counting fingers, hand movements, light 
perception or no light perception.
At least two 45⁰ wide-angle field digital retinal 
photography images per eye were taken by an experi-
enced ophthalmic technician. Mydriatic 2-field digital 
photography, one centered on the optic disc and the 
other on the macula was carried out in all DM patients 
attending the screening. Images were reviewed for the 
presence and stage of DR or clinically significant mac-
ular edema (CSME) by an ophthalmologist. Levels of 
DR or CSME were defined according to definitions 
used in the Early Treatment Diabetic Retinopathy 
Study (ETDRS)9. Mild NPDR was defined as the 
presence of one or more microaneurysms only. Moder-
ate NPDR was defined as the presence of microaneu-
rysms and blot hemorrhages with or without any ad-
ditional lesions such as hard exudates, cotton wool 
spots, intraretinal microvascular abnormalities 
(IRMA), venous beading, but less pronounced than in 
severe NPDR. Severe NPDR was defined as the pres-
ence any of the following (4:2:1): extensive (>20) in-
traretinal hemorrhages in each of 4 quadrants; defini-
tive venous beading in 2+ quadrants or more; promi-
nent IRMA in 1+ quadrant or more, and no signs of 
PDR. The presence of PDR was determined by assess-
ment of retinal neovascularizations, growth of abnor-
mal vessels or/and preretinal or vitreous hemorrhage. 
CSME was defined as thickening of the retina at or 
within 500 µm of the center of the macula; hard exu-
dates at or within the center 500 µm from the center of 
macula, if associated with thickening of retina.
The following grading categories of DR were used: 
without DR, mild NPDR, moderate NPDR, severe 
NPDR, PDR, CSME, and ungradable. Retinal photo-
graphs were considered ungradable if the retina could 
not be visualized appropriately, i.e. when retinal vessels 
were not visible within 1 disc diameter of the center of 
the fovea, and fine vessels were not visible across the 
surface of the optic disc.
Additional nondiabetic clinical findings on retinal 
photographs, such as age-related macular degenera-
tion, glaucoma suspect optic neuropathy, cataract, cho-
roidal nevus, or other nondiabetic causes of retinopa-
thy (retinal vein occlusion, branch retinal vein occlu-
sion) were also recorded.
The recommended follow-up time for patients 
without DR was 12 months, for patients with mild 
NPDR 8-10 months, and for those with moderate 
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NPDR 6-8 months. Patients graded as severe NPDR, 
PDR or CSME were classified as having vision-
threatening DR, thus immediate referral to our De-
partment was recommended. For patients with un-
gradable finding, referral to ophthalmologist for com-
plete ophthalmologic examination in a few months 
was recommended. For patients with additional non-
diabetic findings, referral to ophthalmologist for com-
plete ophthalmologic examination as soon as possible 
or within a few months, according to diagnosis, was 
recommended.
After reviewing and grading retinal images, a re-
port and follow-up or referral recommendation by the 
ophthalmologist was entered into patient medical re-
cords. A letter that included patient diagnosis and rec-
ommended follow-up time or referral recommenda-
tion was generated and mailed to patients.
The screening results for DR were analyzed, fo-
cused on diagnosis made, referral rates and follow-up 
recommendations in all DM patients screened, the 
subgroup of type 1 DM patients and subgroup of new-
ly diagnosed type 2 DM patients. Statistical descrip-
tive analysis was carried out using IBM SPSS Statis-
tics version 22.0 for Windows.
Results
A total of 1428 DM patients were screened for DR 
in the twelve-month period and all 2856 eyes of these 
patients were included in this database review. The 
mean age of DM patients was 63.67 years (standard 
deviation (SD) 12.11); there were 840 (58.8%) male 
and 588 (41.2%) female patients. Of these 1428 DM 
patients, 27 (1.9%) were diagnosed with type 1 DM 
and 1401 (98.1%) with type 2 DM; 217 (15.2%) pa-
tients were only on diet therapy, 817 (57.2%) received 
additional oral antidiabetic medication, and 394 
(27.6%) had additional insulin therapy. The mean du-
ration of DM was 7.82 (SD 7.99) years in all DM pa-
tients. The mean VA was 0.78 (SD 0.24) in all 2856 
eyes. Out of these 1428 DM patients, 1048 (73.4%) 
were referred by their family physician and 380 (26.6%) 
by a diabetologist. Out of these 1401 type 2 DM pa-
tients, 353 (25.2%) had newly diagnosed type 2 DM.
Ungradable findings were recorded in 2.8% of all 
screened retinal photographs; 85.2% of all screened 
eyes were without DR. In 12% of all screened eyes, the 
presence of DR or CSME was recorded, as follows: 
6.9% of the eyes were graded as mild NPDR, 2.3% as 
moderate NPDR, 0.7% as severe NPDR, 0.6% as 
PDR and 1.5% as CSME. Accordingly, vision-threat-
ening DR, which included severe NPDR, PDR and 
CSME, was found in 2.8% of all screened eyes. Addi-
tional nondiabetic clinical findings on retinal photo-
graphs were recorded in 5.2% of screened eyes, includ-
ing age-related macular degeneration in 2.5%, glauco-
ma suspect optic neuropathy in 0.6%, cataract in 1.1%, 
choroidal nevus in 0.7%, and other nondiabetic causes 
of retinopathy (retinal vein occlusion, branch retinal 
vein occlusion) in 0.6% of cases.
Of all DM patients screened, 3.2% were referred 
immediately to our Department because of vision-
threatening DR and 9% were referred to ophthalmol-
ogist for complete ophthalmologic examination be-
cause of ungradable retinal photographs or additional 
nondiabetic clinical findings, as soon as possible or in 
a few months, according to diagnosis.
The DM patient self-reported data on modifiable 
risk factors for DR, including hyperglycemia, hyperten-
sion, hyperlipidemia and obesity, were unreliable and 
insufficient and therefore not included in the analysis.
The subgroup of 54 eyes in 27 type 1 DM patients 
were analyzed separately. The mean age of type 1 DM 
patients was 30.04 (SD 10.31) years; there were 16 
(59.3%) female and 11 (40.7%) male patients, and all 
were on insulin therapy. The mean duration of type 1 
DM was 15.15 (SD 10.28) years. The mean VA was 
0.93 (SD 0.12) in all 54 eyes. Out of these 27 type 1 
DM patients, 12 (44.4%) were referred by their family 
physician and 15 (55.6%) by a diabetologist.
None of type 1 DM screened retinal photographs 
was ungradable. In type 1 DM group, 74.1% of 
screened eyes were without DR, while the presence of 
DR or CSME was recorded in 25.9% of screened eyes, 
as follows: 16.7% of eyes were graded as mild NPDR, 
3.7% as moderate NPDR, 3.7% as PDR and 1.8% as 
CSME. Accordingly, vision-threatening DR, which 
included severe NPDR, PDR and CSME, was found 
in 5.5% of type 1 DM screened eyes. Additional non-
diabetic clinical finding of choroidal nevus on retinal 
photographs was recorded in 3.7% of screened type 1 
DM eyes.
Of all type 1 DM patients screened, 5.5% were re-
ferred immediately to our Department because of vi-
sion-threatening DR and 3.7% were referred to oph-
thalmologist for complete ophthalmologic examina-
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tion because of additional nondiabetic clinical findings 
as soon as possible or in a few months, according to 
diagnosis.
The subgroup of 706 eyes in 353 newly diagnosed 
type 2 DM patients were separately analyzed. The 
mean age of newly diagnosed type 2 DM patients was 
62.73 (SD 11.75) years; there were 212 (60.1%) male 
and 141 (39.9%) female patients; 127 (36.0%) patients 
were only on diet therapy, 212 (60.1%) received addi-
tional oral antidiabetic medication and 14 (4.0%) had 
additional insulin therapy. The mean duration of newly 
diagnosed type 2 DM was 0.52 (SD 0.13) years. The 
mean VA was 0.79 (SD 0.24) in all 706 eyes. Out of 
these 353 newly diagnosed type 2 DM patients, 282 
(79.9%) were referred by their family physician and 71 
(20.1%) by a diabetologist.
Ungradable findings were recorded in 3.1% of 
newly diagnosed type 2 DM screened retinal photo-
graphs; 92.5% of newly diagnosed type 2 DM screened 
eyes were without DR; the presence of DR or CSME 
was recorded in 4.3% of newly diagnosed type 2 DM 
screened eyes, as follows: 3.5% of eyes were graded as 
mild NPDR, 0.7% as moderate NPDR and 0.1% as 
CSME. Accordingly, vision-threatening DR includ-
ing CSME was found in 0.1% of newly diagnosed 
type 2 DM screened eyes. Additional nondiabetic 
clinical findings on retinal photographs were found in 
5.7% of newly diagnosed type 2 DM eyes, i.e. age-re-
lated macular degeneration in 2.3%, glaucoma suspect 
optic neuropathy in 0.3%, cataract in 1.1%, choroidal 
nevus in 1.0% and other nondiabetic causes of reti-
nopathy (retinal vein occlusion, branch retinal vein oc-
clusion) in 1.0% of cases.
Of all newly diagnosed type 2 DM patients 
screened, 0.3% were referred immediately to our De-
partment because of vision-threatening DR and 5.7% 
were referred to ophthalmologist for complete oph-
thalmologic examination because of ungradable retinal 
photographs or additional nondiabetic clinical find-
ings as soon as possible or in a few months, according 
to diagnosis.
Discussion
This study analyzed screening results on DR col-
lected at Diabetic Retinopathy Screening Service 
Centre, Department of Ophthalmology, Maribor Uni-
versity Clinical Centre, Maribor, Slovenia in 2017, 
which was the second full year after launching the 
screening for DR program. Out of 1428 DM patients 
screened in this study, 1.9% were diagnosed with type 
1 DM and 98.1% with type 2 DM, 25.2% of these 
with newly diagnosed type 2 DM. Study results re-
vealed 85.2% of all screened eyes to be without DR, 
2.8% were ungradable and 12% had varying stages of 
DR. Vision-threatening DR was found in 2.8% and 
additional nondiabetic findings in 5.2% of all screened 
eyes, age-related macular degeneration in most of 
them. Of all DM patients screened, 3.2% were referred 
immediately to our Department because of vision-
threatening DR and 9% were referred to ophthalmol-
ogist for complete ophthalmologic examination be-
cause of ungradable retinal photographs or additional 
nondiabetic clinical findings. In the group of type 1 
DM, 74.1% of screened eyes were without DR and 
25.9% were with varying stages of DR. In the same 
group, vision-threatening DR was found in 5.5% and 
additional nondiabetic finding of choroidal nevus in 
3.7% of screened eyes. Of all type 1 DM patients 
screened, 5.5% were referred immediately to our De-
partment because of vision-threatening DR and 3.7% 
were referred to ophthalmologist for complete oph-
thalmologic examination due to additional nondia-
betic clinical findings. In the group of newly diagnosed 
type 2 DM, 92.5% of screened eyes were without DR, 
3.1% were ungradable and 4.3% were with varying 
stages of DR. In this group, vision-threatening DR 
was recorded in 0.1% and additional nondiabetic find-
ings in 5.7% of screened eyes, most of them with age-
related macular degeneration. Of all newly diagnosed 
type 2 DM patients screened, 0.3% were referred im-
mediately to our Department due to vision-threaten-
ing DR and 5.7% were referred to ophthalmologist for 
complete ophthalmologic examination because of un-
gradable retinal photographs or additional nondiabetic 
clinical findings.
Schellini et al. report on the presence of DR of 
varying and undefined stages in 7.6% of 407 screened 
self-reported type 2 DM patients with mean age of 
58.8 years and unknown duration of DM18. In our 
study, 12% of all screened eyes in 1428 DM patients 
showed varying stages of DR, which could be ascribed 
to the fact that we included type 1 DM and type 2 
DM patients with higher mean age of 63.7 years and 
longer duration of DM in comparison to the above 
mentioned study.
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In the Gutenberg Health Study, the weighted 
prevalence of DR in newly diagnosed screening-de-
tected type 2 DM was 13%; out of 285 newly diag-
nosed screening-detected type 2 DM patients, 12% 
had mild NPDR, 0.6% moderate NPDR and 0.3% 
PDR, with no cases of severe NPDR or diabetic mac-
ulopathy19. The Hoorn Screening Study found a higher 
prevalence of DR in screening-detected type 2 DM of 
7.6% as compared to 1.9% in those with newly diag-
nosed type 2 DM in general practice20. In our study, 
80% of 353 newly diagnosed type 2 DM patients were 
referred for screening for DR by their family physician 
and 20% by a diabetologist; the presence of DR or 
CSME was found in 4.3%, including mild NPDR in 
3.5%, moderate NPDR in 0.7% and CSME in 0.1% of 
the screened eyes.
Papavasileiou et al. in their retrospective twelve-
month database review of systematic DR screening in 
15196 DM patients found referable vision-threaten-
ing DR in 4.94% of patients21. In contrast, in our study 
that included less DM patients, referable vision-
threatening DR was found in 2.8% of all screened eyes 
in 1428 DM patients.
Tsui et al. provided a snapshot of teleretinal screen-
ing for DR in 120 DM patients and report that 15% 
had varying stages of NPDR, no PDR was found, 5% 
were ungradable images, 13.3% were glaucoma suspect 
and 10.0% had age-related macular degeneration; 
55.8% of screened DM patients were referred to an eye 
department for further ophthalmic evaluation, includ-
ing any level of DR and any other additional nondia-
betic clinical finding22. In our study, varying stages of 
DR were recorded in 12% of all screened eyes of 1428 
DM patients; 6.9% of eyes had mild NPDR, 2.3% 
moderate NPDR, 0.7% severe NPDR, 0.6% had PDR 
and 1.5% had CSME. In our study, 2.8% of screened 
images were ungradable and additional nondiabetic 
findings were detected in 5.2% of the screened eyes. In 
our study, 3.2% of all DM patients screened were re-
ferred immediately to our Department because of vi-
sion-threatening DR and 9% were referred to oph-
thalmologist for complete ophthalmologic examina-
tion due to ungradable retinal photographs or addi-
tional nondiabetic clinical findings.
The main strength of this study was a relatively 
large sample size, above all newly diagnosed type 2 
DM patients. All DM patients were also screened by a 
standardized protocol of digital retinal photography 
evaluated for the presence and stage of DR or CSME 
and subsequently graded by an ophthalmologist. 
Therefore, additional nondiabetic clinical findings on 
retinal photographs could also be detected by the oph-
thalmologist, who recommended follow-up time, re-
ferral for further ophthalmic evaluation according to 
diagnosis, or referral to our Department for further 
treatment when vision-threatening DR was detected. 
Unfortunately, only limited information was available 
on the major modifiable risk factors for DR. We could 
not obtain measures of glycemic control, blood pres-
sure, lipid concentration and body mass index. The pa-
tient self-reported data on these risk factors were un-
reliable and insufficient. Wang et al. report on a sur-
prisingly small number of DM patients with DR, less 
than 50%, who were aware of the importance of glyco-
sylated hemoglobin, only 17% understood its ideal 
level, significance and physiology, although younger 
age and postsecondary education were significantly as-
sociated with due understanding of glycosylated he-
moglobin23. Therefore, public education by family phy-
sician, diabetologist or ophthalmologist on DM and 
prevention of associated complications including DR 
is important. It is estimated that in developing coun-
tries, half of DM patients do not undergo fundus ex-
amination at least once a year24. Family physicians and 
diabetologists must be informed and educated by oph-
thalmologists on the current DR screening and refer-
ral guidelines to ensure early detection and prompt 
intervention for DM patients with vision-threatening 
DR. The study by Schoenfeld et al. found that more 
than one-third of DM patients do not follow the stan-
dard screening guidelines25. Thus, education is crucial 
to prevent DM and DR.
In conclusion, in this study, a small proportion of 
screened DM patients with detected DR had vision-
threatening DR, demonstrating that screening for DR 
enables early detection and prompt treatment of DM 
related visual impairment.
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Sažetak
PRIKAZ REZULTATA DVANAESTOMJESEČNOG PROBIRA  
NA DIJABETIČKU RETINOPATIJU
T. Gračner
Cilj je prikazati rezultate analize dvanaestomjesečne baze podataka probira na dijabetičku retinopatiju (DR). U retro-
spektivnoj studiji analizirano je 1428 bolesnika s dijabetesom melitusom (DM) pregledanih tijekom 2017. godine. Oftalmo-
log je pregledao snimke očne pozadine na prisutnost i stupanj DR te na prisutnost drugih nedijabetičkih promjena. Primije-
njen je sljedeći sustav stupnjevanja DR: bez DR, blaga neproliferativna DR (NPDR), umjerena NPDR, teška NPDR, pro-
liferativna DR (PDR), klinički značajan makularni edem (clinically significant macular edema, CSME) te nerazvrstani. Teška 
NPDR, PDR i CSME razvrstani su kao za vid ugrožavajuća DR. Od 1428 bolesnika s DM, 27 ih je imalo DM tip 1, 1401 
DM tip 2, od potonjih je 353 imalo novootkriveni DM tip 2. Od svih pregledanih očiju 85,2% ih je bilo bez DR, 2,8% 
 nerazvrstanih, 12% je imalo različite stupnjeve DR. Kod 2,8% svih pregledanih očiju nađena je za vid ugrožavajuća DR, u 
5,2% nađene su dodatne nedijabetičke promjene. Bez DR je bilo 92,5% očiju novootkrivenih dijabetičara s DM tipa 2, 3,1% 
je bilo nerazvrstanih, 4,3% je imalo različite stupnjeve DR. Kod 0,1% očiju novootkrivenih dijabetičara s DM tipa 2 nađena 
je za vid ugrožavajuča DR, a u 5,7% nađene su dodatne nedijabetičke promjene. U zaključku, mali udio pregledanih dija-
betičara s otkrivenom DR imao je za vid ugrožavajuću DR.
Ključne riječi: Dijabetes melitus; Dijabetička retinopatija; Probir; Proliferativna retinopatija; Makulopatija
